Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems

Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma

(2017) Georg Karpel-Massler et al.   Expert Opinion on Drug Discovery

Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL

(2017) Georg Karpel-Massler et al.   Nature Communications

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma

(2017) Chiaki Tsuge Ishida et al.   Oncotarget

Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma

(2017) Chiaki Tsuge Ishida et al.   Oncotarget

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers

(2016) G. Karpel-Massler et al.   CLINICAL CANCER RESEARCH

Dual modulation of MCL-1 and mTOR determines the response to sunitinib

(2016) Mohamed Elgendy et al.   JOURNAL OF CLINICAL INVESTIGATION

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

(2016) Stephan Stilgenbauer et al.   LANCET ONCOLOGY

Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic–Induced Apoptosis

(2016) Patrick Antonietti et al.   MOLECULAR CANCER THERAPEUTICS

A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate

(2016) Michael E Pacold et al.   Nature Chemical Biology

FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation

(2016) J Tong et al.   ONCOGENE

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo

(2016) Georg Karpel-Massler et al.   Oncotarget

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo

(2016) Georg Karpel-Massler et al.   Oncotarget

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

(2016) Sandy Amorim et al.   Lancet Haematology

Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells

(2015) R. Wang et al.   CLINICAL CANCER RESEARCH

Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

(2015) Shiv K. Gupta et al.   JNCI-Journal of the National Cancer Institute

ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells

(2015) Nadine Johnson-Farley et al.   LEUKEMIA & LYMPHOMA

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

(2015) Anthony C. Faber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo

(2015) Georg Karpel-Massler et al.   Oncotarget

Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

(2015) Shiv K. Gupta et al.   JNCI-Journal of the National Cancer Institute

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner

(2015) Irina Kiprianova et al.   NEOPLASIA

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma

(2014) Adam L. Green et al.   NEURO-ONCOLOGY

PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma

(2014) Georg Karpel-Massler et al.   PLoS One

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

(2012) R. Lapalombella et al.   BLOOD

Multiple BH3 Mimetics Antagonize Antiapoptotic MCL1 Protein by Inducing the Endoplasmic Reticulum Stress Response and Up-regulating BH3-only Protein NOXA

(2011) Tina C. Albershardt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1

(2010) M. J. Seltzer et al.   CANCER RESEARCH

A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications

(2010) Zhi Sheng et al.   NATURE MEDICINE

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

(2009) Martin Schwickart et al.   NATURE

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

(2008) K E Tagscherer et al.   ONCOGENE